Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Oktober 2020 16:30 ET | Quelle: Eidos Therapeutics, Inc.

Eidos Therapeutics Reports Third Quarter 2020 Financial Results and Business Update

SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provided an...
07. August 2020 16:30 ET | Quelle: Eidos Therapeutics, Inc.

Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors

SAN FRANCISCO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in...
06. August 2020 16:30 ET | Quelle: Eidos Therapeutics, Inc.

Eidos Therapeutics Reports Second Quarter 2020 Financial Results and Business Update

SAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the second quarter ended June 30, 2020 and provided an...
08. Mai 2020 16:30 ET | Quelle: Eidos Therapeutics, Inc.

Eidos Therapeutics Reports First Quarter 2020 Financial Results and Business Update

SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the first quarter ended March 31, 2020 and provided an...
26. Februar 2020 16:30 ET | Quelle: Eidos Therapeutics, Inc.

Eidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business Update

SAN FRANCISCO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2019 and...
16. November 2019 18:58 ET | Quelle: Eidos Therapeutics, Inc.

CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular...
16. November 2019 17:30 ET | Quelle: Eidos Therapeutics, Inc.

BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular...
31. Oktober 2019 16:30 ET | Quelle: Eidos Therapeutics, Inc.

Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update

SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial...
30. September 2019 07:00 ET | Quelle: Eidos Therapeutics, Inc.

Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need...
19. September 2019 08:00 ET | Quelle: Eidos Therapeutics, Inc.

Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference on...

Nächste Seite